COMMUNIQUÉS West-GlobeNewswire
-
GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
13/06/2024 - 15:19 -
FibroBiologics Set to Join Russell 2000® Index
13/06/2024 - 15:31 -
Results of Annual General Meeting
13/06/2024 - 15:35 -
Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET
13/06/2024 - 16:13 -
Oregon Health Authority Selects Acentra Health to Implement Division of the State’s Health-Related Social Needs Benefits for 1115 Medicaid Waiver Demonstration
13/06/2024 - 16:15 -
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
13/06/2024 - 17:00 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 mai 2024
13/06/2024 - 18:00 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
13/06/2024 - 18:00 -
Noom Announces Strategic Expansion of Executive Team with Key Leadership Appointments
13/06/2024 - 18:14 -
ACTG Announces Launch of its First HIV Cure Clinical Trial in Africa
13/06/2024 - 18:18 -
From Awareness to Action on Global Fatty Liver Day
13/06/2024 - 18:42 -
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
13/06/2024 - 21:00 -
Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
13/06/2024 - 22:00 -
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
13/06/2024 - 22:01 -
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
13/06/2024 - 22:01 -
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
13/06/2024 - 22:01 -
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
13/06/2024 - 22:01 -
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
13/06/2024 - 22:05 -
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
13/06/2024 - 22:05
Pages